Mutual of America Capital Management LLC Boosts Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Mutual of America Capital Management LLC grew its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.6% during the second quarter, according to its most recent filing with the SEC. The firm owned 48,905 shares of the medical equipment provider’s stock after acquiring an additional 2,605 shares during the period. Mutual of America Capital Management LLC’s holdings in Intuitive Surgical were worth $21,755,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Capital Research Global Investors bought a new stake in shares of Intuitive Surgical in the 1st quarter worth approximately $374,390,000. Coatue Management LLC boosted its position in shares of Intuitive Surgical by 65.7% in the 4th quarter. Coatue Management LLC now owns 1,301,595 shares of the medical equipment provider’s stock worth $439,106,000 after purchasing an additional 516,054 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Intuitive Surgical by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after purchasing an additional 493,126 shares in the last quarter. Edgewood Management LLC boosted its position in shares of Intuitive Surgical by 7.9% in the 4th quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock worth $1,731,016,000 after purchasing an additional 374,667 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in shares of Intuitive Surgical by 51.2% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 893,341 shares of the medical equipment provider’s stock worth $356,524,000 after purchasing an additional 302,382 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insiders Place Their Bets

In other Intuitive Surgical news, Director Amal M. Johnson sold 2,943 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the completion of the sale, the director now owns 12,275 shares in the company, valued at approximately $5,441,507.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Intuitive Surgical news, Director Amy L. Ladd sold 450 shares of the stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the transaction, the director now owns 821 shares of the company’s stock, valued at approximately $402,519.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Amal M. Johnson sold 2,943 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 53,120 shares of company stock worth $25,528,753. Corporate insiders own 0.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Barclays boosted their price target on Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research report on Thursday, July 18th. Piper Sandler upped their price objective on Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Truist Financial upped their price objective on Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Evercore ISI lowered their price objective on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a research report on Friday, July 19th. Finally, Citigroup upped their price objective on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Price Performance

NASDAQ:ISRG opened at $483.32 on Wednesday. The firm has a market capitalization of $171.43 billion, a price-to-earnings ratio of 87.24, a price-to-earnings-growth ratio of 5.41 and a beta of 1.39. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $496.18. The business has a fifty day moving average price of $465.50 and a 200-day moving average price of $423.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. The firm had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. Intuitive Surgical’s revenue was up 14.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.18 EPS. On average, equities research analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.